Tag Results

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

9 results found for `GlaxoSmithKline`
Showing page 1 of 1

Blog

Glaxit

Neil Woodford 12 May 2017 4 min read

Over a holding period of more than fifteen years, we have consistently believed that GlaxoSmithKline was capable of delivering growth and realising shareholder value.

Read more

Insights

Equity Income Fund update, February 2017

Mitchell Fraser-Jones 17 March 2017 4 min read

February provided a more positive environment for the fund than we have seen in recent months.

Read more

Insights

Equity Income Fund update, December 2016

Mitchell Fraser-Jones 18 January 2017 4 min read

The final month of 2016 marked the end of a difficult year for the fund.

Read more

Insights

Equity Income Fund update, November 2016

Mitchell Fraser-Jones 16 December 2016 5 min read

November was an eventful month for financial markets, with the outcome of the US presidential election prompting significant intra-month volatility and an acceleration of the correction in bond markets.

Read more

Insights

Equity Income Fund update, October 2016

Mitchell Fraser-Jones 17 November 2016 5 min read

October was a challenging month for the fund, with concerns about the prospect of a Clinton victory in the US presidential elections weighing negatively on sentiment towards health care stocks.

Read more

Blog

British science is in great shape

Neil Woodford 2 March 2015 4 min read

I have been an investor in the pharmaceutical industry for most of my career and have for a long time been fascinated by the opportunity for innovation in this sector to not only benefit society but, in turn, deliver great returns to shareholders.

Read more

Insights

Fund roundup July 2014

Mitchell Fraser-Jones 5 August 2014 5 min read

The UK stock market posted a small negative return during July. Having moved broadly sideways all year so far, the market took a nervous step downwards in the last couple of days of July…

Read more

Blog

Top 10 holdings, 30 June 14

Mitchell Fraser-Jones 7 July 2014 1 min read

Neil has been very careful in building a portfolio that avoids sectors that he believes are vulnerable to a faltering global economy. There is significant emphasis on the tobacco and pharmaceutical sectors.

Read more

Blog

Drug deal

Mitchell Fraser-Jones 22 April 2014 1 min read

GlaxoSmithKline and Novartis have this morning announced a transformational deal involving their consumer healthcare, vaccines and oncology businesses.

Read more

What are the risks?

  • The value of the fund and any income from it may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The ongoing charges figure is charged to capital, so the income of the fund may be higher but capital growth may be restricted or capital may be eroded
  • The fund may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits – some of these security types could increase the fund′s volatility and increase the level of indirect charges to which the fund is exposed
  • The fund may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the sterling value of investments to decrease or increase
  • The fund may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund, and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund′s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address Beaufort House, 51 New North Road, Exeter, EX4 4EP.

© 2019 Woodford Investment Management Ltd.
All rights reserved.

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.

Privacy Preference Center

Experience Tracking

Lets our analytics service track you across our different websites and enables data sharing among our different marketing tools.

AMCV_[Tracker ID]@AdobeOrg (Adobe), [Tracker ID]@AdobeOrg (Adobe)
Adobe Analytics (helps us provide you with more relevant experiences and content based on your likely interests). Cookies: demdex, dextp, dpm, DST, DSTJS
Twitter personalisation (by better understanding how devices are related, Twitter can use information from one device to help personalize the Twitter experience on another device). Cookies: personalization_id
Heap Analytics (provides metrics on user behaviour and actions throughout the site). Cookies: _gid, _hp2_id.[Tracker ID],_hp2_props.[Tracker ID], _ga, _mkto_trk, optimizelyBuckets, optimizelyEndUserId, optimizelySegments, raygun4js-userid, _attribution_referrer, _csrf
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: _tmae ,ev_sync_dd,ev_sync_yh,everest_g_v2,gglck

Traffic Metrics

Allows Woodford to aggregate information on website usage and popular content

_ga, _gid
Google Analytics (tracks and reports website traffic and user behaviour): Cookie: CONSENT
New Relic (application and server performance monitoring – allows us to spot problems with our website code and improve them to keep things running smoothly). Cookie: JSESSIONID
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: __qca,__smToken, _ga, _mkto_trk, _rtbmedia

Search History

Populates the 'recent searches' section of the website navigation.

wf__recent_searches_untracked

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?